Uwe Siebert, Prof., MD, MPH, MSc, ScD
Prof. of Public Health (UMIT), Adjunct Prof. of Health Policy and Management (Harvard Univ.)
UMIT, Dept. Public Health&HTA/ ONCOTYROL, Area 4 HTA&Bioinformatics/ Harvard School Public Health, Center for Health Decision Science, Dept. Health Policy&Management/ Harvard Medical School, Institute for Technology Assessment&Dept. Radiology
Dept. of Public Health & HTA/ Area 4 HTA & Bioinformatics/ Dept. Health Policy & Management/ Institute for Technology Assessment
Eduard Wallnoefer Center I
Hall in Tyrol/ Innsbruck/ Boston
Austria
6060/ 6020/ 02115
Papers:
3G-3
WHEN IS ENOUGH EVIDENCE ENOUGH? VALUE-OF-INFORMATION ANALYSIS FOR PRIORITIZING ADDITIONAL OUTCOMES RESEARCH ON THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
5N-3
THE ONCOTYROL PROSTATE CANCER OUTCOME AND POLICY MODEL - LESSONS LEARNED FROM NATURAL HISTORY CALIBRATION
COST-EFFECTIVENESS OF THE SEQUENTIAL APPLICATION OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA PATIENTS IN THE UNITED STATES
AM1
SMDM CORE COURSE: INTRODUCTION TO MEDICAL DECISION ANALYSIS (DECISION-ANALYTIC MODELING)
TRA-2-5
*TOP RANKED ABSTRACT AT THE 15TH BIENNIAL EUROPEAN MEETING* COMBINING MARKOV STATES: A COMPARISON OF ANALYTICAL AND HEURISTIC METHODS FOR DERIVING THE HAZARD RATES OF A COLLAPSED MARKOV STATE